Tøndel, Kristin

Scientist

E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Phone: +47-6496-5283

Present position: Scientist (Centre for Integrative Genetics, CIGENE)

Current research activity: Data analysis/chemometrics and bioinformatics. Analysing output from deterministic mathematical models and relating it to the model input using multivariate data analysis.

Degrees: Dr. ing.(PhD) in molecular modelling and bioinformatics from the Norwegian University of Science and Technology (NTNU) in Trondheim, 2004. Siv. ing. in physical chemistry from NTNU, 1999.
   
Professional background: Consultant at Grenland Group Technology ASA, Oslo (2006-2009), working with early phase concept studies for the oil and gas industry. Postdoc at the Department of Cancer Research and Molecular Medicine, Faculty of Medicine, NTNU (2004-2006), working with molecular modelling, chemometrics, drug design and bioinformatics. Visiting scientist in the Bioinformatics group at the Centre for Molecular Biology and Neuroscience (CMBN) at Rikshospitalet-Radiumhospitalet and the University of Oslo (UiO) (2005-2006).

Research experience: The main focus of my research has been on protein structure modelling and design of selective protein inhibitors. My work includes both use of existing methods and development of new drug design methods especially suitable for use with protein structure models built by homology modelling. I have developed a method for prediction of homology model accuracy with Partial Least Squares Regression (PLSR), and in collaboration with Prof. Finn Drabløs and Endre Anderssen at NTNU, I have developed a new method for analysis of protein surface properties (Protein Alpha Shape Similarity Analysis (PASSA), and a method for virtual screening and estimation of binding affinities between a protein and various drug candidates (PAS-Dock). I have utilised these methods for rational design of selective inhibitors of the cancer-related protein Tyrosine kinase 2 (Tyk2), and suggested five promising drug candidates.

Selected publications:

  • Kristin Tøndel, Endre Anderssen and Finn Drabløs, Protein Alpha Shape Similarity Analysis (PASSA): A New Method for Mapping Protein Binding Sites. Application in the Design of a Selective Inhibitor of Tyrosine Kinase 2, Journal of Computer-Aided Molecular Design, 2002, 16, 831-840.
  • Kristin Tøndel, Chung F. Wong and J. Andrew McCammon, Computational Analysis of the Interactions Between the Angiogenesis Inhibitor PD173074 and Fibroblast Growth Factor Receptor 1, Journal of Theoretical and Computational Chemistry, 2003, 2, 43-56.
  • Heather Wieman, Kristin Tøndel, Endre Anderssen and Finn Drabløs, Homology-Based Modelling of Targets for Rational Drug Design, Mini-Reviews in Medicinal Chemistry, 2004, 4, 793-804.
  • Kristin Tøndel, Prediction of Homology Model Quality with Multivariate Regression, Journal of Chemical Information and Computer Sciences, 2004, 44, 1540-1551.
  • Kristin Tøndel and Finn Drabløs, Design of Selective Inhibitors of Tyrosine Kinase 2, Letters in Drug Design and Discovery, 2005, 2, 507-515.
  • Kristin Tøndel, Endre Anderssen and Finn Drabløs, Protein Alpha Shape (PAS) Dock: A new gaussian-based score function suitable for docking in homology modelled protein structures, Journal of Computer-Aided Molecular Design, 2006, Online First.